Results 181 to 190 of about 742,291 (286)

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Inactivation of PRMT5 by PARP Inhibitors Confers High Susceptibility in MTAP-Deficient Cancers. [PDF]

Cancers (Basel)
Liu Q, Sheng Y, Lin F, Tan H, Chang Y, Lu X, Chen H, Du C.   +7 more
europepmc   +1 more source

Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models

Cancer Science, EarlyView.
Dietary NA restriction converts the effect of NAMPT inhibition from cytostatic to cytotoxic in SCLC in vivo. ABSTRACT Small‐cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. We previously showed that nicotinic acid riboside (NAR) sustains NAD biosynthesis in vivo and compensates for NAMPT inhibition in SCLC models ...
Kyoji Tsurumi, Miyuki Nomura, Mai Ouchi, Shigehiro Yagishita, Naohiko Kikuchi, Taku Sato, Mami Morita, Yoji Yamashita, Kayoko Hayashi, Tomoyoshi Soga, Akinobu Hamada, Tatsuro Fukuhara, Nobuhiro Tanuma   +12 more
wiley   +1 more source

Survival Outcomes and Sensitivity of PARP Inhibitors in Platinum-Sensitive Ovarian Cancer: A Retrospective Study. [PDF]

Cancer Med
Zhang X, Wang Z, Gu Y, Fang H, Wang Y, Fang C, Wu N.   +6 more
europepmc   +1 more source

Decreased Expression by a Chemically Modified siRNA to PTBP1 Seriously Affects Warburg Effect in Colorectal Cancer Cells

Cancer Science, EarlyView.
Chemically modified siR‐PTBP1 disrupts the Warburg effect by reprogramming pyruvate kinase splicing from PKM2 to PKM1. This metabolic shift activates the TCA cycle, increases ATP production, and excessive ROS generation, and ultimately induces apoptotic cell death in colorectal cancer cells.
Keita Matsumoto, Hirokatsu Hayashi, Yoshihisa Tokumaru, Seito Fujibayashi, Noriki Mitsui, Masahide Endo, Takeshi Horaguchi, Yuji Hatanaka, Ryoma Yokoi, Chika Mizutani, Masashi Kuno, Masahiro Fukada, Ryuichi Asai, Itaru Yasufuku, Yuta Sato, Jesse Yu Tajima, Yoshihiro Tanaka, Remi Nakashima, Yukihiro Akao, Nobuhisa Matsuhashi   +19 more
wiley   +1 more source

Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody-Drug Conjugates. [PDF]

Cancers (Basel)
Sharaf B, Al-Rwashdeh M, El Khatib O, Al-Ibraheem A, Abu Fara A, Ismail A, Alkasrawi H, Abdalla M, Jehad S.   +8 more
europepmc   +1 more source

The DNA/RNA Helicase SETX Maintains R‐Loop Homeostasis to Promote Chemoresistance in Ovarian Cancer

Cancer Science, EarlyView.
SETX maintains R‐loop homeostasis by resolving excessive R‐loops, thereby promoting tumor initiation and chemoresistance. Deficiency of SETX leads to accumulation of unsolved pathological R‐loops, resulting in irreparable DNA damage and ultimately leading to tumor suppression and chemosensitivity.
Zi‐Wei Hu, Tu‐Nan Xu, Zi‐Ying Wang, Xin Zheng, Duan‐Yong Feng, Xiao‐Min Wang, Er‐Suo Jin, Ming Ren, Xiao‐Min Yang, Xian‐Chao Zhang, Xuan Che, Wei‐Wei Pan, Zha‐Jun Zhan, Shu‐Qun Cheng   +13 more
wiley   +1 more source

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

JAMA Oncol
Haggstrom L, Lee YC, Barretina-Ginesta MP, Jaeger A, Woelber L, Woopen H, Rhind M, Frenel JS, Aanum A, Bischof K, Mongillo M, Brodsky AL, Ledermann J, Ghezelayagh TS, Boere I, Kaiser S, Maximiano C, Rosengarten O, Safra T, Pertejo A, Cecere S, Ray-Coquard I, Lheureux S, Glasspool R, Gil-Martin M, Tookman L, Kim SI, Mittelstadt S, Corbellas Aparicio M, Palacio I, Martin-Lorente C, Kristeleit R, de la Cueva H, Ottevanger N, Quindós Varela M, Yoshida H, Link T, Gaba L, Marquina G, Burdett N, Johannet P, Reichenbach J, Park-Simon TW, Klecker PH, González-Martín A, Marth C, Liebrich C, Dzotsenidze L, Heublein S, Kasherman L, Perez C, Masvidal M, Guillén Sentís P, de Gregorio N, Hemptenmacher F, Hilpert F, Sehouli J, Scott C, Tucker KM, Dong J, Fortuno C, Spurdle AB, Friedlander M, Gynecologic Cancer InterGroup Collaboration Into Exceptional Responders to PARP Inhibitors (GCIG-CERP).   +63 more
europepmc   +1 more source

PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implications. [PDF]

Transl Oncol
Li J, Mu D, Li J, Lan M, Wu W, Zhang S, Dai Y.   +6 more
europepmc   +1 more source

PARP Inhibitors in Lung Cancer [PDF]

Journal of Thoracic Oncology, 2012
openaire   +2 more sources